Literature DB >> 28803992

P-REX1 amplification promotes progression of cutaneous melanoma via the PAK1/P38/MMP-2 pathway.

Jinhua Wang1, Hajime Hirose2, Guanhua Du1, Kelly Chong2, Eiji Kiyohara2, Isaac P Witz3, Dave S B Hoon4.   

Abstract

P-REX1 (PIP3-dependent Rac exchange factor-1) is a guanine nucleotide exchange factor that activates Rac by catalyzing exchange of GDP for GTP bound to Rac. Aberrant up-regulation of P-REX1 expression has a role in metastasis however, copy number (CN) and function of P-REX1 in cutaneous melanoma are unclear. To explore the role of P-REX1 in melanoma, SNP 6.0 and Exon 1.0 ST microarrays were assessed. There was a higher CN (2.82-fold change) of P-REX1 in melanoma cells than in melanocytes, and P-REX1 expression was significantly correlated with P-REX1 CN. When P-REX1 was knocked down in cells by P-REX1 shRNA, proliferation, colony formation, 3D matrigel growth, and migration/invasiveness were inhibited. Loss of P-REX1 inhibited cell proliferation by inhibiting cyclin D1, blocking cell cycle, and increased cell apoptosis by reducing expression of the protein survivin. Knockdown of P-REX1 expression inhibited cell migration/invasiveness by disrupting P-REX1/RAC1/PAK1/p38/MMP-2 pathway. Assessment of patient tumors and disease outcome demonstrated lower distant metastasis-free survival among AJCC stage I/II/III patients with high P-REX1 expression compared to patients with low P-REX1 expression. These results suggest P-REX1 plays an important role in tumor progression and a potential theranostic target.
Copyright © 2017. Published by Elsevier B.V.

Entities:  

Keywords:  Copy number; Melanoma; P-REX1; PAK1/p38/MMP-2

Mesh:

Substances:

Year:  2017        PMID: 28803992     DOI: 10.1016/j.canlet.2017.08.001

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  5 in total

1.  Inter-Tumor Heterogeneity-Melanomas Respond Differently to GM-CSF-Mediated Activation.

Authors:  Adi Moshe; Sivan Izraely; Orit Sagi-Assif; Sapir Malka; Shlomit Ben-Menachem; Tsipi Meshel; Metsada Pasmanik-Chor; Dave S B Hoon; Isaac P Witz
Journal:  Cells       Date:  2020-07-13       Impact factor: 6.600

Review 2.  RAC1 Activation as a Potential Therapeutic Option in Metastatic Cutaneous Melanoma.

Authors:  Paula Colón-Bolea; Rocío García-Gómez; Berta Casar
Journal:  Biomolecules       Date:  2021-10-20

3.  Interleukin enhancer-binding factor 2 promotes cell proliferation and DNA damage response in metastatic melanoma.

Authors:  Xiaoqing Zhang; Matias A Bustos; Rebecca Gross; Romela Irene Ramos; Teh-Ling Takeshima; Gordon B Mills; Qiang Yu; Dave S B Hoon
Journal:  Clin Transl Med       Date:  2021-10

Review 4.  P21-Activated Kinase 1: Emerging biological functions and potential therapeutic targets in Cancer.

Authors:  Dahong Yao; Chenyang Li; Muhammad Shahid Riaz Rajoka; Zhendan He; Jian Huang; Jinhui Wang; Jin Zhang
Journal:  Theranostics       Date:  2020-08-01       Impact factor: 11.556

5.  Phosphatidylinositol-3,4,5-trisphosphate dependent Rac exchange factor 1 is a diagnostic and prognostic biomarker for hepatocellular carcinoma.

Authors:  Yi Cai; Qiao Zheng; De-Jiao Yao
Journal:  World J Clin Cases       Date:  2020-09-06       Impact factor: 1.337

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.